Amgen Says Lumakras With Vectibix Approved by FDA for Metastatic Colorectal Cancer

Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
293.91 USD | -0.93% |
|
-4.65% | +12.61% |
Feb. 11 | Amgen Insider Sold Shares Worth $7,341,123, According to a Recent SEC Filing | MT |
Feb. 10 | Piper Sandler Adjusts Amgen Price Target to $329 From $310, Maintains Overweight Rating | MT |